Omrix' vascular sealant:
This article was originally published in Clinica
Executive Summary
The US FDA has given Omrix Biopharmaceuticals the all-clear to expand the market for its Evicel haemostat to use in vascular surgery. The liquid fibrin sealant, which was previously approved for use in liver surgery, can now also be marketed to peripheral vascular surgeons, cardiac surgeons, plastic surgeons performing microvascular anastomoses, transplant surgeons, and trauma surgeons performing vascular repair. The Kiryat Ono, Israel firm believes that the vascular surgery market is approximately twice the size of the liver surgery market. It also expects to gain a general haemostasis in surgery indication for Evicel in the first quarter of 2008. Evicel is marketed by Ethicon, a Johnson & Johnson company.